| Iovance Biotherapeutics Inc (IOVA) | |||
|---|---|---|---|
| 12.03 0.39 (3.35%) | 04-29 16:00 | ||
| Open: | 11.79 | Pre. Close: | 11.64 |
| High: | 12.11 | Low: | 11.72 |
| Volume: | 3,642,823 | Market Cap: | 3,360(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 16.10 One year: 18.10 |
| Support: | Support1: 11.01 Support2: 9.16 |
| Resistance: | Resistance1: 13.78 Resistance2: 15.50 |
| Pivot: | 12.01  |
| Moving Averages: | MA(5): 11.76  MA(20): 12.40 MA(100): 11.05 MA(250): 8.17 |
| MACD: | MACD(12,26): -0.58 Signal(12,26,9): -0.56 |
| %K %D: | %K(14,3): 29.12 %D(3): 24.32 |
| RSI: | RSI(14): 43.80 |
| 52-Week: | High: 18.33 Low: 3.21 Change(%): 87.1 |
| Average Vol(K): | 3-Month: 9005 10-Days: 3569 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 12.121 - 12.168 | 12.168 - 12.221 |
| Low: | 11.594 - 11.644 | 11.644 - 11.701 |
| Close: | 11.936 - 12.017 | 12.017 - 12.11 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IOVA ] has closed below upper band by 48.9%. Bollinger Bands are 42.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
| Company profile |
|---|
| Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | |
| Shares Float (M) | 279.31 |
| % Held by Insiders | 210900000.00 |
| % Held by Institutions | 0.57 |
| Shares Short (K) | 46710 |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | -449009984.000 |
| Book Value (p.s.) | |
| Profit Margin | |
| Operating Margin | -25.00 |
| Return on Assets (ttm) | 156.9 |
| Return on Equity (ttm) | -39.9 |
| Qtrly Rev. Growth | 1190000.0 |
| Gross Profit (p.s.) | |
| Sales Per Share | -138.831 |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | -1.89 |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | -361.82 |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | 0.48 |
| Price to Book value | |
| Price to Sales | -0.09 |
| Price to Cash Flow | 3.11 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | 46380000.000 |
